Young women with stable CHD are more likely to develop myocardial ischemia with mental stress than men of similar age

Asthma may significantly raise risk of cardiovascular events

Active asthma may significantly raise risk of heart attack

Secondhand marijuana smoke may damage blood vessels as much as tobacco smoke

Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the Taxus Liberté Paclitaxel-Eluting Coronary Stent

Randomized, Double Blind Trial of 6 vs. 12 Months of Dual Antiplatelet Therapy After DES-Implantation (ISAR-SAFE)

Is 6 Months DAPT Post Coronary Stenting Non Inferior to 24 Months? The Italic/Italic+ Randomized Trial. Results of the One Year Primary Endpoint (ITALIC)

Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study (DAPT Study)

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Patients with Multiple Atherosclerotic Risk Factors: A Randomized Controlled Trial

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using Coronary CT Angiography: Primary Results of FACTOR- 64, a Randomized Controlled Trial (FaCTor-64)

ODYSSEY ALTERNATIVE: Efficacy and Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients with Statin Intolerance as Defined by a Placebo Runin and Statin Rechallenge Arm

IMPROVE IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Patients with Multiple Atherosclerotic Risk Factors: A Randomized Controlled Trial (Lecture, Discussant, Panel Discussion – Long Version)

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using Coronary CT Angiography: Primary Results of FACTOR- 64, a Randomized Controlled Trial (Lecture, Discussant, Panel Discussion – Long Version)

ODYSSEY ALTERNATIVE: Efficacy and Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients with Statin Intolerance as Defined by a Placebo Runin and Statin Rechallenge Arm

IMPROVE IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes (Lecture, Discussant, Panel Discussion – Long Version)

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both: A 2 × 2 Factorial Mendelian Randomization Study

Gilles Montalescot's perspective on new findings of DAPT

FDA's statement on new DAPT safety and efficacy findings by Mary Ross Southworth

FDA's perspective on new DAPT safety findings

The results of the Japanese Primary Prevention Program

Karol Watson on the ODYSSEY ALTERNATIVE trial results

Donald Lloyd-Jones on the IMPROVE-IT trial results

Pamela Douglas on the FACTOR-64 trial results

Karol Watson on the IMPROVE-IT trial results

Neil Stone on the IMPROVE-IT trial results

Gordon Tomaselli on AHA2014 novelties in the treatment of atrial fibrillation

John A Elefteriades on Atenolol vs. Losartan in Marfan Syndrome trial results

Euan Ashley on the results of INHERIT Trial

Dhruv Kazi on the increasing incidence of infective endocarditis in England

David Adams on the surgical treatment of moderate ischemic mitral regurgitation

Robert Harrington's Summary on the AHA2014 Scientific Sessions Highlights